Salivary Levels of Human Neutrophil Peptide (HNP) 1-3 in Patients with Recurrent Aphthous Stomatitis and Behçet’s Disease: A Cross-Sectional Study in Iran

Saffari, Simin; Mirfeizi, Zahra; Gholamalizadeh, Hanieh; Mehrad-Majd, Hasan; Mahmoudi, Mahmoud; Hashemzadeh, Kamila

Salivary Levels of Human Neutrophil Peptide (HNP) 1-3 in Patients with Recurrent Aphthous Stomatitis and Behçet’s Disease: A Cross-Sectional Study in Iran

Document Type : Original Article

Authors

Simin Saffari ¹

Zahra Mirfeizi ¹

Hanieh Gholamalizadeh ²

Hasan Mehrad-Majd ³

Mahmoud Mahmoudi ⁴

Kamila Hashemzadeh ⁵

¹ Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

² Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

³ Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

⁴ Immunology Research Center, Bu Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

⁵ Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Background:
Recurrent oral ulcers constitute the most common complaint of patients with Behçet’s disease (BD) and recurrent aphthous stomatitis (RAS). Enhanced innate immune response and neutrophilic activity might be a possible etiopathogenesis of BD. This study aimed to determine the significance of salivary HNP 1-3 in BD and RAS patients and detect their correlation with different clinical presentations, disease activity, and characteristics of oral ulcers.
Methods:
This cross-sectional study included 25 BD patients and 25 RAS patients as well as 25 healthy participants. 5 cc of unstimulated saliva were collected and levels of HNP 1-3 were measured by ELISA. Other data were obtained through interviews, examination, and reviews of medical records. SPSS 25.0 was used to analyze the data.
Results:
Salivary HNP 1-3 levels were not significantly different between the study groups (P=0.282). Duration of oral ulcers did not correlate with HNP 1-3 levels in RAS and BD patients (P>0.05). Also, BD patients with involvements other than oral ulcers were not found to have different levels of HNP 1-3 comparing to those who did not manifest these conditions.
Conclusions:
The validity of HNP 1-3 to be used as a probable biological marker for evaluation, diagnosis, and estimation of disease activity in patients with BD and RAS is still questionable due to our results.

Keywords

Saliva

Human neutrophil peptide

HNP 1-3

Behçet’s disease

recurrent aphthous stomatitis

Subjects

Internal Medicine

Refaat MM, Ahmed Said AM, Abdelmonsef Ebeid A, Yehia Elmazly A, Sayed Sheha D. Ocular manifestations and complications in a cohort of Behçet’s disease patients in a tertiary hospital. Egypt Rheumatol. 2021;43(1):81-4. doi: 10.1016/j.ejr.2020.07.007.
Yazici H, Seyahi E, Hatemi G, Yazici Y. Behçet syndrome: a contemporary view. Nat Rev Rheumatol. 2018;14(2):107-19. doi: 10.1038/nrrheum.2017.208.
Yazici H, Ugurlu S, Seyahi E. Behçet syndrome: is it one condition? Clin Rev Allergy Immunol. 2012;43(3):275-80. doi: 10.1007/s12016-012-8319-x.
Mazzoccoli G, Matarangolo A, Rubino R, Inglese M, De Cata A. Behçet syndrome: from pathogenesis to novel therapies. Clin Exp Med. 2016;16(1):1-12. doi: 10.1007/s10238-014- 0328-z.
Sánchez-Bernal J, Conejero C, Conejero R. Recurrent aphthous stomatitis. Actas Dermosifiliogr (Engl Ed). 2020;111(6):471- 80. doi: 10.1016/j.ad.2019.09.004.
Mattioli I, Bettiol A, Saruhan-Direskeneli G, Direskeneli H, Emmi G. Pathogenesis of Behçet’s syndrome: genetic, environmental and immunological factors. Front Med (Lausanne). 2021;8:713052. doi: 10.3389/fmed.2021.713052.
Mumcu G, Ergun T, Inanc N, Fresko I, Atalay T, Hayran O, et al. Oral health is impaired in Behçet’s disease and is associated with disease severity. Rheumatology (Oxford). 2004;43(8):1028-33. doi: 10.1093/rheumatology/keh236.
Balt J, Uehara O, Abiko Y, Jamyanjav B, Jav S, Nagasawa T, et al. Alteration of oral flora in Mongolian patients with Behçet’s disease: a multicentre study. Clin Exp Rheumatol. 2020;38 Suppl 127(5):80-5.
Dale BA, Tao R, Kimball JR, Jurevic RJ. Oral antimicrobial peptides and biological control of caries. BMC Oral Health. 2006;6(Suppl 1):S13. doi: 10.1186/1472-6831-6-s1-s13.
da Silva BR, de Freitas VA, Nascimento-Neto LG, Carneiro VA, Arruda FV, de Aguiar AS, et al. Antimicrobial peptide control of pathogenic microorganisms of the oral cavity: a review of the literature. Peptides. 2012;36(2):315-21. doi: 10.1016/j. peptides.2012.05.015.
Ganz T, Selsted ME, Szklarek D, Harwig SS, Daher K, Bainton DF, et al. Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest. 1985;76(4):1427-35. doi: 10.1172/ jci112120.
Perazzio SF, Soeiro-Pereira PV, Dos Santos VC, de Brito MV, Salu B, Oliva ML, et al. Soluble CD40L is associated with increased oxidative burst and neutrophil extracellular trap release in Behçet’s disease. Arthritis Res Ther. 2017;19(1):235. doi: 10.1186/s13075-017-1443-5.
Neves FS, Spiller F. Possible mechanisms of neutrophil activation in Behçet’s disease. Int Immunopharmacol. 2013;17(4):1206-10. doi: 10.1016/j.intimp.2013.07.017.
Rifaioglu EN, Bülbül Şen B, Ekiz Ö, Cigdem Dogramaci A. Neutrophil to lymphocyte ratio in Behçet’s disease as a marker of disease activity. Acta Dermatovenerol Alp Pannonica Adriat. 2014;23(4):65-7.
Mumcu G, Cimilli H, Karacayli U, Inanc N, Ture-Ozdemir F, Eksioglu-Demiralp E, et al. Salivary levels of antimicrobial peptides HNP 1-3, Ll-37 and S100 in Behcet’s disease. Arch Oral Biol. 2012;57(6):642-6. doi: 10.1016/j. archoralbio.2011.11.003.
Mumcu G, Cimilli H, Karacayli Ü, Inanc N, Türe-Özdemir F, Eksioglu-Demiralp E, et al. Salivary levels of HNP 1-3 are related to oral ulcer activity in Behçet’s disease. Int J Dermatol. 2013;52(10):1198-201. doi: 10.1111/j.1365- 4632.2012.05504.x.
International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD). The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338-47. doi: 10.1111/ jdv.12107.
Slebioda Z, Szponar E, Kowalska A. Etiopathogenesis of recurrent aphthous stomatitis and the role of immunologic aspects: literature review. Arch Immunol Ther Exp (Warsz). 2014;62(3):205-15. doi: 10.1007/s00005-013-0261-y.
Hatemi G, Yazici Y, Yazici H. Behçet’s syndrome. Rheum Dis Clin North Am. 2013;39(2):245-61. doi: 10.1016/j. rdc.2013.02.010.
Direskeneli H. Behçet’s disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis. 2001;60(11):996-1002. doi: 10.1136/ard.60.11.996.
Zhang Z, Su Q, Zhang L, Yang Z, Qiu Y, Mo W. Diagnostic value of hemoglobin and neutrophil-to-lymphocyte ratio in Behcet disease. Medicine (Baltimore). 2019;98(52):e18443. doi: 10.1097/md.0000000000018443.
Dale BA, Fredericks LP. Antimicrobial peptides in the oral environment: expression and function in health and disease. Curr Issues Mol Biol. 2005;7(2):119-33. doi: 10.1093/jac/ dki103.
Kucukkolbasi H, Kucukkolbasi S, Ayyildiz HF, Dursun R, Kara H. Evaluation of hbetaD-1 and hbetaD-2 levels in saliva of patients with oral mucosal diseases. West Indian Med J. 2013;62(3):230-8.
Küçükkolbaşi H, Küçükkolbaşi S, Dursun R, Ayyildiz F, Kara H. Determination of defensin HNP-1 in human saliva of patients with oral mucosal diseases. J Immunoassay Immunochem. 2011;32(4):284-95. doi: 10.1080/15321819.2011.569045.
Polesello V, Zupin L, Di Lenarda R, Biasotto M, Pozzato G, Ottaviani G, et al. DEFB1 polymorphisms and salivary hBD- 1 concentration in oral lichen planus patients and healthy subjects. Arch Oral Biol. 2017;73:161-5. doi: 10.1016/j. archoralbio.2016.10.008.
Mizukawa N, Sugiyama K, Ueno T, Mishima K, Takagi S, Sugahara T. Defensin-1, an antimicrobial peptide present in the saliva of patients with oral diseases. Oral Dis. 1999;5(2):139- 42. doi: 10.1111/j.1601-0825.1999.tb00078.x.
Shaat RM, El Meadawy S, Rizk EM, Abd Elgawad MS, Elsaid TO. The significance of α-defensins 1-3 in Behcet’s disease: a case-control study among Egyptian patients. Egypt Rheumatol Rehabil. 2020;47(1):26. doi: 10.1186/s43166-020-00026-1.
Ahn JK, Hwang JW, Oh JM, Bae EK, Lee J, Lee YS, et al. Increased α-defensin-1 expression in Korean patients with Behcet’s disease. Joint Bone Spine. 2011;78(6):593-7. doi: 10.1016/j.jbspin.2011.01.012.
Ozuguz P, Karabulut AA, Tulmac M, Kisa U, Kocak M, Gunduz O. Markers of endothelial dysfunction and evaluation of vascular reactivity tests in Behçet disease. Angiology. 2014;65(10):937-43. doi: 10.1177/0003319713512413.
Yücel Ç, Omma A, Sertoğlu E, Sezer S, Turhan T, Özgürtaş Evaluation of atherogenic laboratory markers in Behçet’s disease patients with vascular involvement. Arch Med Sci. 2020;16(3):531-7. doi: 10.5114/aoms.2018.79139.